Alessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.
Alessandro Gronchi, MD, chair of Sarcoma Service, IRCCS Foundation National Cancer Institute, Milan, Italy, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.
The international, prospective TRASTS study, which was presented during the 2020 ASCO Virtual Scientific Program, evaluated the utility of trabectedin (Yondelis) in combination with radiation therapy in patients with localized myxoid liposarcoma.
Prior data showed that trabectedin alone induced tumor shrinkage in 40% to 50% of patients in this population, Gronchi says. Additionally, radiation therapy alone induces tumor shrinkage in about 40% of patients.
Findings from the study showed that 53% of patients treated had tumor shrinkage with 10% or less viable tumor remaining, says Gronchi.
Additionally, 30% of patients achieved a partial response and 70% achieved stable disease with the combination, Gronchi adds.
Ultimately, the combination of trabectedin and radiation therapy appears to be a feasible and well-tolerated regimen in patients with localized myxoid liposarcoma, Gronchi concludes.